title: High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma.
abstract: Forty patients with refractory Hodgkin's disease (24 patients) or non-Hodgkin's lymphoma (16 patients) who were considered for high-dose therapy but not for autologous bone marrow transplantation (ABMT) due to BM metastases, previous pelvic irradiation, a history of marrow involvement by tumor or hypocellular marrow in conventional harvest sites received high-dose therapy and autologous peripheral blood (PB) hematopoietic stem cell transplantation. Disappearance of circulating neutrophils and development of RBC and platelet transfusion-dependence was followed, in the evaluable patients, by reappearance of 0.5 x 10(9)/L circulating granulocytes and sufficient platelets to obviate the need for platelet transfusions at a median of 25 days after transplantation. Twenty-three patients experienced a clinical complete remission (CR). The projected 2-year event-free survival was 24% for all 40 patients and 49% for the non-Hodgkin's lymphoma patients. The projected 18-month event-free survival for the Hodgkin's disease patients was 15%. PB stem cell transplantation provided an opportunity to administer high-dose salvage therapy to patients with refractory lymphoma who otherwise were not candidates for such therapy. For some of those patients, the high-dose therapy produced prolonged survival, free of tumor progression.
authors.affiliation: Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68105.
authors.forename: A
authors.initials: A
authors.lastname: Kessinger
authors.forename: J O
authors.initials: JO
authors.lastname: Armitage
authors.forename: D M
authors.initials: DM
authors.lastname: Smith
authors.forename: J D
authors.initials: JD
authors.lastname: Landmark
authors.forename: P J
authors.initials: PJ
authors.lastname: Bierman
authors.forename: D D
authors.initials: DD
authors.lastname: Weisenburger
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001804:Blood Transfusion, Autologous; D002330:Carmustine; D002648:Child; D003520:Cyclophosphamide; D004334:Drug Administration Schedule; D005047:Etoposide; D005260:Female; D005500:Follow-Up Studies; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007937:Leukapheresis; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide; D002330:Carmustine